Combination of the chemokine receptor type 2 (CCR2) antagonist DMX-200 and candesartan for COVID-19: a randomised controlled trial
Authors:
- Daniel Vincent O'HAraDODaniel Vincent O'HAra
- Abhinav BassiABAbhinav Bassi
- Arlen WilcoxAWArlen Wilcox
- Vivekanand JhaVJVivekanand Jha
- Vinay RathoreVRVinay Rathore
- Sanjay D'CRuzSDSanjay D'CRuz
- Thomas L SnellingTSThomas L Snelling
- Mark JonesMJMark Jones
- James TotterdellJTJames Totterdell
- Ashpak BangiABAshpak Bangi
- Manish Kumar JainMJManish Kumar Jain
- Carol PollockCPCarol Pollock
Open Access
Abstract
Objective To determine whether a chemokine receptor type 2 antagonist, DMX-200 (repagermanium), in combination with an angiotensin receptor blocker, candesartan, improves clinical outcomes in people with COVID-19. Design Prospective, multicentre, double-blind, placebo-controlled trial. Setting Ten acute care hospitals in India. Participants Adults Intervention DMX-200 120 mg two times per day, or placebo, on background of titratable candesartan commencing at 4 mg two times per day, for 28 days. Main outcome measures The primary endpoint was COVID-19 disease severity on a modified WHO Clinical Progression Scale (WHO scale) on day 14. Secondary outcomes included the WHO scale at days 28, 60, 90 and 180; intensive care unit (ICU) admission, respiratory failure or death within 28 days; length of hospitalisation; and requirement for ventilatory support or dialysis. Results Between December 2021 and August 2022, 518 people were screened, with 49 randomised to DMX-200 or placebo on a background of candesartan. The study was terminated early due to recruitment barriers, including an external requirement to restrict enrolment to adults Conclusion Due to recruitment barriers, the study was unable to determine whether DMX-200 improves clinical outcomes in people with COVID-19. Trial registration number ClinicalTrials.gov NCT05122182.Keywords
Funding Information
- Dimerix Bioscience Pty Ltd (N/A)
This publication has 19 references indexed in Scilit:
- Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19JAMA, 2023
- Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin systemCell, 2021
- Coronavirus biology and replication: implications for SARS-CoV-2Nature Reviews Microbiology, 2020
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020
- Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptorNature, 2020
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, ChinaJAMA, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- The Comparative Efficacy and Safety of the Angiotensin Receptor Blockers in the Management of Hypertension and Other Cardiovascular DiseasesDrug Safety, 2014
- A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injuryNature Medicine, 2005
- Propagermanium: a nonspecific immune modulator for chronic hepatitis BJournal of Gastroenterology, 2003